Found 16 articles
QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
QurAlis Corporation today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for QRL-201 for the potential treatment of ALS.
QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies
QurAlis Corporation and Unlearn today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial intelligence (AI) technology.
QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced that the European review has been completed for the Clinical Trial Regulation (CTR) and each participating country has issued a notice of acceptance for QRL-201 for the potential treatment of ALS.
Wave will discontinue development of WVE-004 in C9-associated ALS and frontotemporal dementia after the therapy failed to show any clinical benefit in a mid-stage trial.
Phase IIa data showed AI Therapeutics' ALS candidate increased expression of a target engagement biomarker and led to a 73% reduction in a toxic protein aggregate.
QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
QurAlis Corporation today announced that the first patient has been dosed in its Phase 1 clinical trial of QRL-201 for the treatment of ALS (ANQUR).
Recently, 6 of Viva's portfolio companies have achieved significant results and progress: Mediar and QurAlis have successfully completed financing, while AmacaThera, AceLink, Basking, and TechnoDerma have made smooth progress in their R&D pipelines.
QurAlis has taken a biomarker-driven approach to treating ALS all the way to another bank deposit, closing an oversubscribed $88 million Series B round Thursday.
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
QurAlis Corporation announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million.
The neurodegenerative drug development space saw incremental victories in 2022. Leaders from Eisai, Voyager and QurAlis discuss upcoming milestones.
QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
QurAlis Corporation today announced the authorization of its clinical trial application (CTA) by Health Canada for QRL-201, a first-in-class STATHMIN-2 (STMN2) precision medicine for ALS.
Roundworms are the cornerstone of scientific discoveries that have helped shape how we understand human disease and treatment. BioSpace takes a look at advances in C. elegans research.
QurAlis Presents Data About STATHMIN-2 Role in Neuronal Disease Biology and TDP-43 Biomarker Identification at AD/PD™ 2022
QurAlis Corporation today announced the presentation of preclinical findings from its STATHMIN-2 (STMN2) program,
Researchers have unlocked a key mechanism behind the gene encoding protein UNC13A which could provide new treatment options for ALS and FTD.
QurAlis Presents New Data Confirming Role of STATHMIN-2 in Neuronal Disease Biology at 32nd International Symposium on ALS/MND
QurAlis Corporation today announced the presentation of preclinical findings from its STATHMIN-2 (STMN2) program in poster sessions at the 32nd International Symposium on ALS/MND being held virtually, December 7-10, 2021.
QurAlis' first piece of the puzzle is a protein called stathmin-2, which is encoded by the STMN2 gene.